Clinical Trial Update: Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Imprime PGG in combination with pembrolizumab in advanced melanoma and triple-negative breast cancer has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Triple-negative Breast Cancer

Drugs mentioned

• Imprime PGG
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: HiberCell, Inc. | Conditions: Advanced Melanoma, Triple-Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-07-09